Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8379177 | 0.97 | HTT (0.66) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL13618524 | 0.90 | HTT (0.70) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10722320 | 0.87 | HTT (0.89) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1520613 | 0.84 | HTT (0.89) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL13162411 | 0.84 | HTT (0.96) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL30530619 | 0.84 | HTT (0.89) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10330512 | 0.82 | HTT (0.86) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14825166 | 0.82 | HTT (1.00) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL2538595 | 0.82 | HTT (0.86) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL18726000 | 0.81 | HTT (0.72) | HTTALDH1A1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-2257543-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | AstraZeneca AB (SE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| CN-101501025-A | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2035411-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-0938483-B1 | MUSCARINIC ANTAGONISTS | SCHERING CORP (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-0938483-A2 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1999-09-01 | — | — | EP | disclosed |
| CN-1204327-A | Pharmaceutically active quinazoline compounds | ASTRA PHARMA PROD (GB) | 1999-01-06 | — | — | CN | disclosed |
| WO-1998005292-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE AS MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | HTT 3123/4885ALDH1A1 837/4885CYP2C9 474/4885 |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | HTT 4427/4885ALDH1A1 1847/4885CYP2C9 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.